Amgen strikes Enbrel 'outcomes' contract with Harvard Pilgrim

Pfizer's new Inflectra biosim data puts J&J's Remicade on notice in Crohn's

Roche lawsuit blasts Amgen for 'about-face' on biosimilar patent fights

Pfizer's solo Xeljanz can't match AbbVie's Humira in big RA head-to-head miss

Aurobindo adds to manufacturing with biosimilars plant

EMA raises manufacturing questions over Novartis biosimilar production

Sandoz head: Enbrel biosimilar Erelzi won't launch before 2018, delayed by legal battle

Bad news for biosim makers: FDA sets 'high bar' in interchangeability guidance